FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

D

D

D

D

5.765

5,465

5,365

5,265

5. Relationship of Reporting Person(s) to Issuer

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

1. Name and Address of Reporting Person

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol

ULLIAN ELAINE				<u>VERTEX PHA</u> <u>MA</u> [VRTX]	<u> RM</u>	<u>ACE</u>	<u>UTICAL</u>	(Check	Director Officer (give title	10% (Owner (specify			
(Last)	(First)	(Middle	e)							below)	below)		
C/O VERTEX PHARMACEUTICALS INCORPORATED				d. Date of Earliest Tra .0/01/2014	ansactio	n (Mo	onth/Day/Year)							
50 NORTHERN AVENUE				4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)									X	Form filed by One	e Reporting Pers	son		
BOSTON	•									Form filed by More than One Reporting Person				
(City)	(State)	(Zip)												
		Table I -	Non-Derivati	ve Securities A	cquir	ed,	Disposed	of, or I	Beneficially	Owned				
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V		Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)					
Common Stoc	k		10/01/2014		M		5,000	A	\$34.32	10,265	D			
Common Stoc	k		10/01/2014		S ⁽¹⁾		808	D	\$106.42(2)(3)	9,457	D			
Common Stoc	 k		10/01/2014		S ⁽¹⁾		2,592	D	\$107.48(3)(4)	6.865	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

S⁽¹⁾

S⁽¹⁾

S⁽¹⁾

S⁽¹⁾

1.100

300

100

100

D

D

D

D

\$108.32(3)(5)

\$109.3(3)(6)

\$110.45

\$111.57

	(org., pare, care, marrane, options, convertible cocarriace)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$34.32	10/01/2014		M			5,000	(7)	05/31/2016	Common Stock	5,000	\$0.00	5,000	D	

Explanation of Responses:

Common Stock

Common Stock

Common Stock

Common Stock

- 1. Transaction made pursuant to Ms. Ullian's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$106.42 (range \$105.93 to \$106.89).

10/01/2014

10/01/2014

10/01/2014

10/01/2014

- 3. Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$107.48 (range \$106.93 to \$107.92).
- 5. Open market sales reported on this line occurred at a weighted average price of \$108.32 (range \$107.99 to \$108.81).
- 6. Open market sales reported on this line occurred at a weighted average price of \$109.30 (range \$109.24 to \$109.42).
- 7. Fully vested.

Remarks:

Kenneth L. Horton, Attorney-In-Fact

10/03/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.